Treatment with octreotide does not reduce tumor uptake of 68Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors

Journal of Nuclear Medicine

Volumn 52, Issue 11, 2011, Pages 1679-1683

  Haug, Alexander R ^a,b   Rominger, Axel ^a   Mustafa, Mona ^a   Auernhammer, Christoph ^a,b   Gok̈e, Burkhard ^a   Schmidt, Gerwin P ^b   Wan̈gler, Bjor̈n ^a   Cumming, Paul ^a   Bartenstein, Peter ^a   Hacker, Marcus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Neuroendocrine tumor; PET; Somatostatin; SUV; Treatment

Indexed keywords

GALLIUM EDETATE GA 68; OCTREOTIDE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL; SPLEEN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; YOUNG ADULT;

EID: 80455127123     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.089276     Document Type: Article

References (19)

1. 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36:765-770.
2. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518.
3. 68Ga-DOTA-Tyr3- octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427-1434.
4. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51:1349-1356.
5. Eriksson B, Kloppel G, Krenning E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: well-differentiated jejunal- ileal tumor/carcinoma. Neuroendocrinology. 2008;87:8-19. (Pubitemid 350308290)
6. 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004-2010.
7. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663.
8. Cescato R, Schulz S, Waser B, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med. 2006;47:502-511. (Pubitemid 46768493)
9. Ben-Shlomo A, Schmid H, Wawrowsky K, et al. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab. 2009;94:4342-4350.
10. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38:430-438.
11. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab. 2009;94:654-661.
12. Bruno JF, Xu Y, Berelowitz M. Somatostatin regulates somatostatin receptor subtype mRNA expression in GH3 cells. Biochem Biophys Res Commun. 1994; 202:1738-1743. (Pubitemid 24265973)
13. Dö rr U, Rath U, Sautter-Bihl ML, et al. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med. 1993;20:431-433.
14. Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with 111In-pentetreotide. Neuroendocrinology. 2009;90:184-189.
15. 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:49-57.
16. Reubi JC, Waser B, Cescato R, Gloor B, Stettler C, Christ E. Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J Clin Endocrinol Metab. 2010;95:2343-2350.
17. Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009;50:936-941.
18. Astruc B, Marbach P, Bouterfa H, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol. 2005;45:836-844. (Pubitemid 40875336)
19. Janson ET, Kalkner KM, Eriksson B, Westlin JE, Oberg K. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors. Nucl Med Biol. 1999;26:877-882. (Pubitemid 30047156)